Scientists identify lead for reducing risk of respiratory distress in newborns born to women who develop intrahepatic cholestasis of pregnancy (ICP).
St. Jude study advances understanding of cellular organization and highlights a possible treatment strategy for degenerative diseases like ALS.
Throughout the month of September supporters can join our movement and help support the little warriors at
St. Jude in their big fight against childhood cancer.
St. Jude scientists discover how mutations in the IKZF1 gene lead to high-risk leukemia and identify drugs that may help improve survival.
Researchers show how the most common genetic cause of ALS and a related disorder disrupts normal cell function, results offer hope for targeted therapies.
St. Jude Children’s Research Hospital has received designated Magnet status. Only 7 percent of all U.S. hospitals have received this designation.
Keith Perry has been named as
St. Jude chief information officer (CIO) to provide strategic counsel and leadership for the hospital’s information technology initiatives.
Jinghui Zhang, Ph.D., an international expert in the analysis of genomic data, will lead the growth of innovative effort in newly dedicated space supported by Brooks Brothers.
St. Jude scientists have discovered how the p53 protein works outside the cell nucleus to trigger cell death. The results could aid cancer therapy.
A subset of medulloblastoma tumors briefly stopped growing or disappeared during treatment with the targeted drug vismodegib.
Martha Perine Beard and Paul Ayoub Jr. have been named the new chairs of the ALSAC/
St. Jude Boards of Directors and Governors.
St. Jude researchers have discovered a potential new method for determining whether masses in the chest cavity are a fungal infection or a tumor without performing a biopsy.
Roberts, an internationally recognized leader in cancer epigenetics, will oversee the country’s only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children.
St. Jude receive grants from the NIGMS for a Center for Precision Medicine in Leukemia to optimize curative treatments, translate genomics, and inform genomics methods for other disease treatments.
St. Jude scientists use new methods to show that one type of stem cell is superior to another for treating retinal degeneration in research that could advance such treatments
St. Jude Children's Research Hospital has ranked on Great Place to Work and Fortune's "100 Best Workplaces for Millennials" list.
St. Jude scientists created a second-generation of spectinomycin to combat bacteria that are a common cause of respiratory and other infections.
St. Jude discovery lays the foundation for developing new, much needed chemotherapy agents and finds evidence that anti-cholesterol drugs called statins slow growth of ependymoma tumor cells.
St. Jude discovered how an immune system protein called AIM2 plays a role in determining the aggressiveness of colon cancer.
Evidence from the Childhood Cancer Survivor Study (CCSS) suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors.
St. Jude Children’s Research Hospital investigators presented the research at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
Each year, the FedEx
St. Jude Classic provides St. Jude patients with support and a unique opportunity to interact with professional golfers and celebrities.
J. Paul Taylor, M.D., Ph.D., of
St. Jude Children's Research Hospital, has been recognized as one of the nation’s leading biomedical researchers by the Howard Hughes Medical Institute.
Researchers have identified three genes that play a pivotal role in the brain tumor choroid plexus carcinoma (CPC), a discovery that lays the groundwork for more effective treatment of this rare, often fatal cancer.
Childhood cancer survivors – especially those whose treatment included brain irradiation or chemotherapy with glucocorticoids – are 14 percent more likely to be obese than their healthy peers.
St. Jude Children’s Research Hospital scientists show that mutations in the DDX3X gene lead to different molecular defects; findings will aid efforts to develop more individualized therapy of medulloblastoma.
Results of the
St. Jude Children’s Research Hospital-led study provide a target for developing novel therapies to tame the inflammation that drives autoinflammatory diseases.
St. Jude Children’s Research Hospital study lays the foundation for more effective treatment of childhood leukemia and a wide range of other disorders using small molecules to reverse glucocorticoid resistance
Hundreds of people gathered in Baltimore to celebrate the life of a local teenager who fought brain cancer at
Addition extends access to clinical trials at
St. Jude to children beyond its physical walls through clinical, research and academic affiliations with medical centers in six states.
Study provides a target for developing novel therapies to tame the inflammation that drives autoinflammatory diseases